Aclaris Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate and Clinical Update
Globe Newswire•06/08/2026•06:59 ET
0
Whiz Insights
- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Validate Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing -
- Timelines Reaffirmed for Upcoming Top Line Results from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 and Phase 2 Trial of Bosakitug (ATI-045) -
Get started
Create a free account to read the full story.